Saliva Direct: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity

Background: Scaling SARS-CoV-2 testing to meet demands of safe reopenings continues to be plagued by assay costs and supply chain shortages. in response. we developed SalivaDirect which received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Methods: We simplified our saliva-based diagnostic test by (1) not requiring collection tubes with preservatives, (2) replacing nucleic acid extraction with a simple enzymatic and heating step, and (3) testing specimens with a dualpiex qRT-PCR assay. Moreover, we validated SalivaDirect with reagents and instruments from multiple vendors to minimize supply chain issues. Findings: From our hospital cohort, we show a high positive agreement (94%) between saliva tested with SalivaDirect and nasopharyngeal swabs tested with a commercial qRT-PCR kit. In partnership with the National Basketball Association (NBA) and National Basketball Players Association (NBPA), we tested 3,779 saliva specimens from healthy individuals and detected low rates of invalid (0.3%) and false-positive (<0.05%) results. Conclusions: We demonstrate that saliva is a valid alternative to swabs for SARS-CoV-2 screening and that SalivaDirect can make large scale testing more accessible and affordable. Uniquely we can designate other laboratories to use our sensitive. flexible and simplified platform under our EUA (https://publichealth.yale.edu/salivadirect/).

Automated summary

SalivaDirect simplifies saliva-based diagnostic testing for SARS-CoV-2, demonstrating high positive agreement with traditional swab testing. This innovative approach can make large scale testing more accessible and affordable, offering an alternative solution to supply chain issues.